Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Hot Products: Multi-pass transmembrane proteins
GMP grade products
| Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
| Antagonizing TSP1/CD36 Polypeptide Blocking the activation of TGF-β1 | Fusion/Recombination protein | Respiratory disease | IPF,PF-ILD | IND | Global (except China) |
| PEGylation CD3 + CD19 bsAb | Monospecific antibody | Immunological disease | Immunodeficiencies | IND | Global |
| Orexin Receptor Antagonist (OX1R and OX2R) | Small molecule | Neurological disease | Insomnia Disorder | Phase III | Global (except China) |
| CD37+CD22 CAR-T | Cell therapy | Oncology/Cancer | AML | PCC | Global |
| CD40 mAb | Monospecific antibody | Oncology/Cancer | Advanced solid tumor | Phase I | Global |
| CD47 Monoclonal Antibody | Monospecific antibody | Oncology/Cancer | Advanced solid tumor,Advanced hematological tumor | IND | Global |
| FRα BsAb-ADC | Bispecific antibody | Oncology/Cancer | Ovarian cancer | Preclinical | Global |
| Her2xCD3 BsAb | Bispecific antibody | Oncology/Cancer | HER2-positive Cancer | Phase I | Global |
| Anti-Her2 II / Anti-Her2 IV Bi-specific antibody ADC | Bioconjugates | Oncology/Cancer | Solid tumor | Preclinical | Global |
| IL10 / IL10RA mAb | Monospecific antibody | Infectious and parasitic diseases | Immunodeficiencies | PCC | Global |
| LAG-3 mAb | Monospecific antibody | Oncology/Cancer | Advanced solid tumor | Phase I | Global |
| PD-1×TIGIT BsAb for Advanced solid tumor | Bispecific antibody | Oncology/Cancer | Cancer | Preclinical | Global |
| SIRPα×PD-1 bsAb | Bispecific antibody | Oncology/Cancer | Advanced solid tumor | Preclinical | Global |
| High selective OX1R/OX2R dual inhibitor treating insomnia | Small molecule | Neurological disease | Insomnia | Phase I | Global |
| ACC inhibitor treating NASH | Small molecule | Metabolic disease | NASH | IND | Global |
| Oxazolidone (new compounds) antibiotics | Small molecule | Infectious and parasitic diseases | gram-positive bacterial infections | IND | Global |
| HIF-PHs inhibitor for CKD and Renal anemia | Small molecule | Blood and Clotting disease | CKD,Renal anemia | Phase I | Global (except China) |
| PI3K/mTOR dual inhibitor | Small molecule | Oncology/Cancer,Respiratory disease | IPF,solid tumor | Phase I | Global (except China) |
| 5-HT1F agonist | Small molecule | Neurological disease | Migraine | Phase I | Global |
| NGF mAb | Monospecific antibody | Neurological disease | Cancer pain | Phase II | Global (except China) |
| TNFα and TGF-β1 inhibitor | Small molecule | Respiratory disease | IPF | Phase II | Global (except China) |
| Capsid Assembly Inhibitors for HBV | Small molecule | Infectious and parasitic diseases | HBV | Phase III | Global (except China) |
| PI3Kδ inhibitor | Small molecule | Oncology/Cancer | Hematologic malignancies | Phase I | Global |
| Capsid Assembly Inhibitors for HBV | Small molecule | Infectious and parasitic diseases | HBV | Phase I | Global (except China) |
| RET high selective inhibitor | Small molecule | Oncology/Cancer | NSCLC,Medullary thyroid cancer,Thyroid cancer | Phase I | Global |
| A SSRI & Partial 5-HT1A Agonist | Small molecule | Neurological disease | Depression | Phase III | Global |
| sGC stimulator | Small molecule | Cardiovascular | PAH,CTEPH,HFrEF,CKD | Phase I | Global |
| SGLT2 inhibitor | Small molecule | Metabolic disease | Diabetes | Phase III | Global (except China) |
| FXR Agonist | Small molecule | Metabolic disease | Diabetic kidney disease | Phase I | Global |
| Anti-GCC humanized antibody | Bispecific antibody | Oncology/Cancer | Solid Tumor | Preclinical | Global |
This web search service is supported by Google Inc.
A-Z
